The Laryngoscope · 2025
Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lim Ji Hyung, Han Dowoon, Velasco Gianfranco C, Seo Young Jun, Han Jae Sang, Park Jung Mee, Seo Jae Hyun, Park So Young, Park Shi Nae
Аннотация
OBJECTIVES: Investigating the efficacy and safety of intratympanic Botulinum toxin (IT-BTX) injection as a novel treatment for middle ear myoclonic tinnitus (MEMT).
METHODS: Medical records and tinnitus questionnaires of the patients with MEMT who underwent IT-BTX were retrospectively reviewed. The efficacy of IT-BTX on MEMT as well as its safety were evaluated by audiology tests and tinnitus questionnaires.
RESULTS: A total of 57 patients who completed the questionnaires at pre- and post-IT-BTX were enrolled. Tinnitus handicap inventory (THI) scores decreased significantly from pre-IT-BTX (44.31 ± 26.8) to 31.42 ± 23.6 (p < 0.001), 32.92 ± 24.9 (p = 0.004), and 25.71 ± 22.9 (p < 0.001) at 1-, 3-, and 6-months post-IT-BTX, respectively. Additionally, visual analog scales (VAS) of loudness (LD), awareness (AW), annoyance (AN), and effect on life (EF) significantly decreased post-IT-BTX (p < 0.05): LD from 4.19 ± 2.4 to 2.47 ± 2.0, 2.89 ± 2.2, and 2.38 ± 1.9 at 1-, 3-, and 6-months; AW from 41.75 ± 29.5 to 24.38 ± 23.3, 26.94 ± 23.3, and 22.10 ± 21.7; AN from 5.00 ± 2.8 to 2.82 ± 2.1, 3.47 ± 2.4, and 2.78 ± 2.2; EF from 4.82 ± 2.8 to 2.89 ± 2.2, 3.28 ± 2.4, and 2.73 ± 2.2 at 1-, 3-, and 6-months post-IT-BTX. Notably, 40.3% of the IT-BTX patients experienced a complete cure of their MEMT symptoms, while 50.8% demonstrated partial resolution after IT-BTX. There were no side effects or complications after IT-BTX during their follow-up period. Comparing delta values between the single injection group and multiple injection group revealed significant differences in VAS LD at the post-1-month time point and between the 1-month and 6-month intervals.
CONCLUSION: IT-BTX is an effective, safe treatment for MEMT, significantly improving symptoms without complications, and offers a promising alternative before middle ear tendon resection.
METHODS: Medical records and tinnitus questionnaires of the patients with MEMT who underwent IT-BTX were retrospectively reviewed. The efficacy of IT-BTX on MEMT as well as its safety were evaluated by audiology tests and tinnitus questionnaires.
RESULTS: A total of 57 patients who completed the questionnaires at pre- and post-IT-BTX were enrolled. Tinnitus handicap inventory (THI) scores decreased significantly from pre-IT-BTX (44.31 ± 26.8) to 31.42 ± 23.6 (p < 0.001), 32.92 ± 24.9 (p = 0.004), and 25.71 ± 22.9 (p < 0.001) at 1-, 3-, and 6-months post-IT-BTX, respectively. Additionally, visual analog scales (VAS) of loudness (LD), awareness (AW), annoyance (AN), and effect on life (EF) significantly decreased post-IT-BTX (p < 0.05): LD from 4.19 ± 2.4 to 2.47 ± 2.0, 2.89 ± 2.2, and 2.38 ± 1.9 at 1-, 3-, and 6-months; AW from 41.75 ± 29.5 to 24.38 ± 23.3, 26.94 ± 23.3, and 22.10 ± 21.7; AN from 5.00 ± 2.8 to 2.82 ± 2.1, 3.47 ± 2.4, and 2.78 ± 2.2; EF from 4.82 ± 2.8 to 2.89 ± 2.2, 3.28 ± 2.4, and 2.73 ± 2.2 at 1-, 3-, and 6-months post-IT-BTX. Notably, 40.3% of the IT-BTX patients experienced a complete cure of their MEMT symptoms, while 50.8% demonstrated partial resolution after IT-BTX. There were no side effects or complications after IT-BTX during their follow-up period. Comparing delta values between the single injection group and multiple injection group revealed significant differences in VAS LD at the post-1-month time point and between the 1-month and 6-month intervals.
CONCLUSION: IT-BTX is an effective, safe treatment for MEMT, significantly improving symptoms without complications, and offers a promising alternative before middle ear tendon resection.